Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, FOB-3, Tampa, FL 33612, USA.
Int J Hematol. 2010 Jan;91(1):124-7. doi: 10.1007/s12185-009-0464-5. Epub 2009 Dec 16.
We describe Influenza A/pandemic 2009/H1N1 in two allogeneic hematopoietic cell transplantation recipients. The main presentation in both cases consisted of flu-like symptoms manifesting as, fever, arthralgias and myalgias. The virus was isolated in one case from a throat swab and in another case following a bronchoalveolar lavage. Both patients received oseltamivir at a dose of 75 mg orally twice day. The dose of oseltamivir was increased to 150 mg twice per day due to the lack of improvement or progression of symptoms. In one case, clinical symptoms resolved without sequelae. In the second case, pulmonary symptomatology continued to deteriorate, despite aggressive polymicrobial treatment, requiring mechanical ventilation and ultimately the patient died from respiratory failure. These cases highlight the potentially serious effect of the ongoing Influenza A/pandemic 2009/H1N1 pandemic in this very vulnerable population and the urgent need to establish emergency preparedness strategies by oncology and bone marrow transplantation staff to face this serious healthcare challenge.
我们描述了两例异基因造血细胞移植受者感染甲型流感/2009 年 H1N1 病毒的情况。两例患者的主要表现均为流感样症状,包括发热、关节痛和肌痛。在一例患者中,病毒是从咽拭子中分离出来的,另一例患者是从支气管肺泡灌洗液中分离出来的。两名患者均接受奥司他韦治疗,剂量为 75 mg 口服,每日两次。由于症状没有改善或进展,奥司他韦的剂量增加到 150 mg,每日两次。一例患者临床症状缓解,无后遗症。第二例患者尽管采用了积极的多微生物治疗,但肺部症状仍持续恶化,需要机械通气,最终患者因呼吸衰竭而死亡。这些病例突显了甲型流感/2009 年 H1N1 大流行在这一非常脆弱人群中可能造成的严重影响,以及肿瘤学和骨髓移植工作人员制定应急准备策略以应对这一严重医疗保健挑战的紧迫性。